Therapeutic potential and mechanistic insights of silibinin targeting cancer-associated fibroblasts in colorectal cancer

Bibliographic Details
Title: Therapeutic potential and mechanistic insights of silibinin targeting cancer-associated fibroblasts in colorectal cancer
Authors: Shenglan He, Jianmei Ji, Kaisi Zhu, Youlan Chen, Xiaowen Xu
Source: Frontiers in Pharmacology, Vol 16 (2025)
Publisher Information: Frontiers Media S.A., 2025.
Publication Year: 2025
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: silibinin, colorectal cancer, cancer-associated fibroblasts, anti-proliferation, antimigration, Therapeutics. Pharmacology, RM1-950
More Details: ObjectiveThis study aims to elucidate the role of SB in inhibiting CRC progression by targeting CAFs and elucidating the underlying mechanisms.MethodsIn this study, a spontaneous CRC model induced by AOM/DSS was used to evaluate the effects of SB on CAFs. Mice were treated with SB, and tumor burden was assessed by colon length. CAFs were isolated post-treatment for transcriptomic analysis to identify differentially expressed genes, with molecular docking providing in silico evidence of SB’s binding to target proteins. CAFs changes were further examined through HE staining, IHC, and assays for cell viability, colony formation, and migration. Integrated bioinformatic analysis elucidated the mechanistic role of SB in CAFs-mediated CRC progression.ResultsIn vivo studies showed that SB effectively reduced POSTN and α-SMA protein levels in CAFs in AOM/DSS-induced CRC mice. Consistently, in vitro experiments demonstrated that SB significantly decreased both protein and mRNA levels of α-SMA and POSTN in fibroblasts (colonic myofibroblast CCD-18Co cell lines.) co-cultured with CRC cell lines (human colorectal adenocarcinoma SW480 and RKO cell lines). SB also inhibited proliferation, colony formation, and migration of CCD-18Co cells. Transcriptomic and integrated bioinformatic analyses further suggested that SB exerts therapeutic effects on CAFs in CRC by modulating key target pathways.ConclusionThese results demonstrated that SB holds promise as a therapeutic agent for targeting CAFs in CRC. This study advances our understanding of SB’s mechanisms, particularly its inhibitory effects on CAFs proliferation, colony formation, and migration.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2025.1527871/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2025.1527871
Access URL: https://doaj.org/article/4e4965ffcdb94c0a94d819df372a4df8
Accession Number: edsdoj.4e4965ffcdb94c0a94d819df372a4df8
Database: Directory of Open Access Journals
More Details
ISSN:16639812
DOI:10.3389/fphar.2025.1527871
Published in:Frontiers in Pharmacology
Language:English